Antiscarring effect of intraoperative bevacizumab in experimental glaucoma
            filtration surgery

Hilgert, Christiana Rebello; Hilgert, A; Odashiro, Alexandre Nakao; Odashiro, Patricia R.; Paranhos, Augusto

doi:10.5935/0004-2749.20180062

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 27 There have been several investigations on the potential anti-scarring effect of anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab in experimental models of GFS. 33 , 40 , 41 The majority of these studies have shown that anti-VEGF agents limited postoperative scarring when given as an adjunct with either MMC 40 or 5-FU, 41 but not as a monotherapy.…”

Section: Discussionmentioning

confidence: 99%

Inhibitory Effects of 3′,4′-Dihydroxyflavonol in a Mouse Model of Glaucoma Filtration Surgery and TGFβ1-Induced Responses in Human Tenon's Fibroblasts

Gaskin

Kong

Shah

et al. 2022

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose Cytotoxic agents such as mitomycin C (MMC) are part of the mainstay treatment for limiting subconjunctival scarring following glaucoma filtration surgery (GFS). However, a safer antifibrotic therapy is clinically needed. The anti-scarring properties of 3′,4′-dihydroxyflavonol (DiOHF) were evaluated in a mouse model of GFS and in cultured human Tenon's fibroblasts (HTFs). Methods GFS was performed in C57BL/6 mice receiving daily intraperitoneal injections of DiOHF or vehicle or a single intraoperative injection of MMC. Eyes were harvested on day 14 for assessment of collagen deposition, expression of alpha-smooth muscle actin (α-SMA), cluster of differentiation 31 (CD31), and 4-hydroxy-2-nonenal (4HNE) in the conjunctiva/Tenon's layer. The inhibitory effects of DiOHF on transforming growth factor β (TGFβ)-induced responses were also assessed in HTFs. Results Treatment with DiOHF demonstrated a reduction in collagen deposition at the GFS site compared to vehicle-treated mice. The degree of 4HNE-positive fluorescence was significantly reduced in DiOHF-treated eyes compared to the other groups, indicating a decrease in oxidative stress. A reduction in expression of α-SMA and CD31 was seen in DiOHF-treated conjunctiva compared to those treated with vehicle. Concordant results were demonstrated in cultured HTFs in vitro . Furthermore, treatment of cultured HTFs with DiOHF also displayed a reduction in the proliferation, migration, and contractility of HTFs. Conclusions Treatment with DiOHF reduces scarring and angiogenesis in the conjunctiva of mice with GFS at a level comparable to MMC. The reduction in oxidative stress suggests that DiOHF may suppress scarring via different mechanisms from MMC. Translational Relevance DiOHF may be a safer and superior wound modulating agent than conventional antifibrotic therapy in GFS.

show abstract